We report a reliable approach for sequencing lymphoma-specific CDRIII regions. CDRIII regions present in DNA prepared from routinely fixed and paraffin-embedded diagnostic lymph node material were amplified by the use of consensus VH and JH primers via PCR. PCR products were subcloned directly, without purification or modification of PCR fragments. Only small amounts of miniprep plasmid DNA of recombinant clones were required for cycle sequencing, resulting in autoradiograms of high quality. The easy and reproducible method which we describe has enabled us to determine the lymphoma-specific CDRIII region in 7/11 high-grade non-Hodgkin's lymphomas as well as in 3/3 cases of ALL and 1/1 case of a centroblastic/centrocytic lymphoma. The obtained sequence data can serve to generate lymphoma-specific oligonucleotides, which then can be used as PCR primers or hybridization probes for the detection of minimal residual disease in individual patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/annonc/5.suppl_1.s79 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO).
Ann Hematol
September 2014
Department of Internal Medicine C-Haematology and Oncology, Stem Cell Transplantation, Ernst-Moritz-Arndt-University, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany,
This study was conducted in order to evaluate allogeneic stem cell transplantation (alloSCT) as consolidation for patients with mantle cell lymphoma (MCL). Patients with MCL were included into two prospective trials OSHO #060 (refractory/relapsed) and #074 (de novo). Induction was rituximab and chemotherapy.
View Article and Find Full Text PDFIntroduction: Acute lymphoblastic leukemia (ALL) cells have unique rearranged immunoglobulin heavy chain (IgH), immunoglobulin light chain (IgK), and T-cell receptor (TCR) genes, which can be used as markers for clonality assay and evaluation of minimal residual disease. In this study, we have evaluated the pattern of IgH, IgK chains, and TCRG/D gene rearrangements in precursor-B ALL.
Materials And Methods: In our prospective study, hyper-variable regions (CDRI and III) of IgH, TCRD (Vδ2-Dδ3 and Dδ2-Dδ3), TCRG (Vγ, VγI, and VγII), and IgK (Vκ-Kde) were studied in 126 cases with diagnosis of B-precursor ALL.
[The diagnostic significance of Ig heavy chain rearrangement detected in B cell lymphoma patients' serum or plasma blood samples].
Zhonghua Nei Ke Za Zhi
June 2005
The Department of Hematology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
Objective: To evaluate the diagnostic significance of detecting immunoglobulin (Ig) heavy chain (IgH) by using serum or plasma as blood samples.
Methods: First, collect serum and plasma blood samples of patients with B-NHL and extract tumor-derived DNAs. Then design the primer to amplify framework3 (Fr3) from the V segment regions to the J regions of the IgH complementary determining region III (CDR-III) gene.
Biallelic IgH rearrangements in patients with indolent lymphoproliferative disorders: molecular and practical implications.
J Cell Physiol
May 2004
1st Department of Internal Medicine, Charles University General Hospital, Prague, Czech Republic.
We report a group of patients (pts) with indolent lymphoproliferative disorder who had both alleles for the immunoglobulin heavy chain genes rearranged (biIgH). This group of 17 pts consisted of 9 small lymphocytic lymphomas (SLL) and 8 chronic lymphocytic leukemia (CLL). The polymerase chain reaction (PCR) amplification of clonal immunoglobulin heavy (IgH) rearrangement using the complementarity determining region III (CDRIII) constantly retrieved two distinct bands in all PCR informative samples of those pts.
View Article and Find Full Text PDFCytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity.
Curr Pharm Des
November 2003
Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston MA 02115, USA.
There is compelling evidence in murine model systems and from human clinical trials that immunotherapy approaches can induce immune responses against tumors. The idiotypic determinants (Id) of the rearranged immunoglobulin proteins of malignant B cells were the first tumor-specific antigens to be recognized and provide a target of an immune mediated response against malignant B cells. Id was thought of as not only tumor-specific but also patient-specific since every patient's malignant B cell clone expresses a unique sequence that is determined by the third complementary determinant regions (CDRIII) of the Id.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!